S&P 500 Dow Jones Nasdaq: Dow Jones crashes, S&P 500, Nasdaq slip as U.S. Stock market analysts make big prediction

Wall Street pulled back from its records on Tuesday following a mixed start to the latest profit reporting season for big U.S. companies. The S&P 500 fell 0.2% from its all-time high set the day before. The Dow Jones Industrial Average dropped 398 points, or 0.8%, from its own record, while the Nasdaq composite slipped 0.1%.

S&P 500 fell 13.53 points to 6,963.74. The Dow Jones Industrial Average dropped 398.21 to 49,191.99, and the Nasdaq composite sank 24.03 to 23,709.87.

U.S. companies are under pressure to deliver strong growth in profits to justify the runs to records their stock prices have made. Analysts expect companies in the S&P 500 index will deliver earnings per share for the final three months of 2025 that are 8.3% higher than a year earlier, according to FactSet.

JPMorgan Chase helped kick off the latest reporting season by delivering weaker profit and revenue than analysts expected. Its stock fell 4.2% and was one of the heaviest weights on the market.

The shortfall may have been because some analysts hadn’t updated their estimates to account for an earnings hit resulting from the bank’s purchase of the Apple Card credit card portfolio. CEO Jamie Dimon sounded relatively optimistic about the U.S. economy, saying “consumers continue to spend, and businesses generally remain healthy.”

Delta Air Lines lost 2.4% despite reporting a stronger profit than analysts expected. Its revenue came up short of Wall Street’s expectations, as did the midpoint of its forecasted range for profit in 2026.

Chipotle Mexican Grill sank 2.3% after saying it’s looking for a new chief marketing officer, a move that surprised analysts.On the winning side of Wall Street were several health care companies that raised their financial forecasts at an industry conference with analysts.

Moderna jumped 17.1% for the biggest gain in the S&P 500 after saying it expects to report revenue for 2025 that’s above the midpoint of the range it had forecast in November. It also offered updates on several products, including a seasonal flu vaccine that could see potential approvals beginning later this year.

Revvity rose 6% after the life sciences company said it expects to report profit for 2025 that’s above the top end of the forecasted range it had earlier given. Its forecast for revenue in the fourth quarter also topped analysts’ expectations.

Cardinal Health added 2.8% after saying it expects to earn at least $10 in adjusted earnings per share in its fiscal 2026 year, up from its prior forecasted range of $9.65 to $9.85.